Abstract 123P
Background
A novel fusion gene of EML4-ALK and ROS 1 has been identified in a subset of non-small-cell lung cancers (NSCLCs). Patients with the ALK-EML4 and ROS1 fusion gene demonstrate unique clinicopathological characteristics and treatment with targeted therapy led to improved survivals.
Methods
Data of advanced NSCLC patients diagnosed between 2016 and 2022 with ALK and ROS1 positivity were analyzed. Detection of ALK was done by IHC or fluorescent in situ hybridization (FISH) and ROS1 was done by FISH.
Results
A total of 776 advanced NSCLC patients between 2016 and 2022 were tested for ALK of which 63(8.1%) were positive. The median age at presentation was 50 years (range,19-80 years). Of 63 patients, 34(54%) were males and 29(46%) were females. Cough (83%) was the most common symptom at presentation followed by dyspnea (73%), anorexia (59%) weight loss (59%) and chest pain (43%). The median duration of symptoms was 3 months. 44(86%) patients were never smokers and 9(14%) patients had history of smoking or tobacco usage. The most common site of metastases was opposite lung(59%), bone(50%) followed by pleural effusion(41%). Brain metastasis were seen in 13(21%) patients. Detection of ALK positivity was done by IHC and FISH in 45(72%) and 18(28%) patients respectively. Of 63 patients, 52 patients received atleast 4 months of treatment and were assessed for survival. First-line therapy was crizotinib, chemotherapy followed by maintenance crizotinib, ceritinib, alectinib in 40(77%), 4(7.7%), 6(11.5%) and 2(3.8%) patients. The median PFS was 16 months (range, 4-52). At a median follow up of 14 months, the 1-year progression free and overall survival was 71% and 75%. The 2 year and 3 year OS were 54% and 30% . Out of 322 patients tested for ROS1, 9(2.8%) were positive for ROS1 translocation and received first-line therapy with Crizotinib. The one year PFS and OS were 75% and 89%.
Conclusions
ALK and ROS1 positivity was seen in 8.1% and 2.8% of advanced NSCLC patients. Majority of patients were never smokers. Opposite lung and bone were the most common site of metastases. 3/4th of the patients had one-year survival rate and the survival rates in the real world are better than reported in the randomized studies. Crizotinib is well tolerated in majority of patients.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
Nizam's Institute of Medical Sciences.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
41P - HLA genotypes modify the age-related penetrance of BRCA1 pathogenic variants in breast cancer patients
Presenter: Ekaterina Kuligina
Session: Cocktail & Poster Display session
Resources:
Abstract
42P - Investigating the influence of extrachromosomal DNA in the progression of non-small cell lung cancer through the TRACERx and PEACE studies
Presenter: Jeanette Kittel
Session: Cocktail & Poster Display session
Resources:
Abstract
43P - MDM2 alterations in primary brain tumors: A potential niche for targeted therapy
Presenter: Diego Gomez Puerto
Session: Cocktail & Poster Display session
Resources:
Abstract
44P - Exploring miR-205 and miR-296 as salivary biomarkers and potential therapeutic targets in oral cancer
Presenter: Thaís Moré Milan
Session: Cocktail & Poster Display session
Resources:
Abstract
45P - Integrative analysis of TCGA DNA methylation, RNA-sequencing, and variant dataset using machine learning in predicting endometrial cancer recurrence
Presenter: Jinhwa Hong
Session: Cocktail & Poster Display session
Resources:
Abstract
46P - The role of microRNA-1246 in early detection of breast cancer: Findings from a systematic review and meta-analysis
Presenter: Muhammed Elfaituri
Session: Cocktail & Poster Display session
Resources:
Abstract
47P - Differential expression of discriminative markers in matched invasion fronts and tumour buds in CRC
Presenter: Laura Grech
Session: Cocktail & Poster Display session
Resources:
Abstract
48P - Transcriptome profiling highlights distinct gene signatures in HER2 high (HER2 3+) and HER 2 low (Her2 1+/2+) breast cancers
Presenter: Tamanna Thakur
Session: Cocktail & Poster Display session
Resources:
Abstract
49P - MiR-155 promotes breast cancer progression by upregulating cancer stemness
Presenter: Jeonghee Han
Session: Cocktail & Poster Display session
Resources:
Abstract
50P - Clinical impact of actionable molecular variants disclosed in late-stage cancer patients by tumor whole-exome sequencing in a prospective single-institution study
Presenter: Christophe Mapendano
Session: Cocktail & Poster Display session
Resources:
Abstract